anti-hsa-miR-210 therapeutics (Rosetta Genomics)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Nameanti-hsa-miR-210 therapeutics (Rosetta Genomics)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionSerum albumin antagonists
TargetsSerum albumin
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRosetta Genomics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRosetta Genomics
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A